Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
GTBP
GTBP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest GTBP ETF News Today | Earnings, Events & Price Alerts
GTBP News
GT Biopharma Reports $28.4 Million Net Loss for FY2025
1d ago
seekingalpha
GT Biopharma Initiates Phase 1 Trial for GTB-5550
Feb 03 2026
Newsfilter
Ventripoint Partners with Nisg̱a'a to Enhance Cardiac Diagnostics with AI Technology
Jan 16 2026
Globenewswire
Ventripoint Partners with Nisg̱a'a Valley to Enhance Cardiac Diagnostics
Jan 16 2026
Newsfilter
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
Jan 16 2026
PRnewswire
GT Biopharma Submits IND for GTB-5550, Aiming for 2026 Clinical Trials
Jan 15 2026
NASDAQ.COM
GT Biopharma (GTBP) Submits IND Application for GTB-5550, Plans Phase 1 Trial in 2026
Jan 15 2026
NASDAQ.COM
GT Biopharma Submits IND for GTB-5550, Targeting $362 Billion Solid Tumor Market
Jan 15 2026
Globenewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 24 2025
Globenewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg Dose
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
Ventripoint Partners with Nisga'a to Enhance Cardiac Diagnostics in Remote Areas
Dec 15 2025
Globenewswire
Ventripoint Partners with Nisga'a to Enhance Cardiac Diagnostics Accessibility
Dec 15 2025
Newsfilter
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4
Dec 11 2025
Newsfilter
Show More News
